ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases today announced the publication of data in the leading scientific journal Frontiers in Immunology.
ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases today announced the publication of data in the leading scientific journal Frontiers in Immunology.
ImmunoQure, a biotech company focused on the research and development of human autoantibodies as therapeutics for the treatment of common human diseases and the international pharmaceutical company Servier today announced the establishment of a Worldwide, exclusive partnership for the development of a therapeutic autoantibody neutralizing interferon- α.
ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today welcomed the establishment of a non-profit charity for APS-1/APECED patients who live in Sardinia.
ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the journal Arthritis & Rheumatology.
ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the leading scientific journal The Journal of Experimental Medicine. In a Worlds-first, the authors have developed a system by which interferon-α (IFNα) levels can be measured in serum, plasma and cerebrospinal fluid.
ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the leading scientific journal Cell, demonstrating that such therapeutics can limit a variety of common human diseases.